HK Stock Market Move | CSTONE PHARMA-B (02616) rose by more than 5% since June, with multiple directors increasing their holdings. CS5007 global clinical development has been fully launched.

CSTONE PHARMA-B (02616) rose more than 5% as of the time of writing, up 4.39% to HK$4.76 with a turnover of HK$10.618 million. In terms of news, according to the latest disclosure from the Hong Kong Stock Exchange, CSTONE PHARMA-B has seen a concentrated increase in holdings by multiple directors. Since early June, Dr. Yang Jianxin, executive director, Dr. Li Wei, non-executive director, and Kenneth Walton Hitchner III, director, have cumulatively increased their holdings by approximately 1.8065 million shares, with a total estimated investment of over HK$8 million. Among them, Dr. Yang Jianxin, who has been CEO since August 2022, has accumulated over 13.38 million shares with his own funds, holding a stake of 4.54%, demonstrating his long-term commitment to the company's development. In addition, CSTONE PHARMA-B began implementing buybacks on June 15th. CSTONE PHARMA-B's core candidate drug CS5007 (EGFR/HER3 bispecific antibody-drug conjugate) has officially received approval for a global multicenter Phase I clinical trial from the Australian Human Research Ethics Committee, signaling the full commencement of its global clinical development. The new generation of innovative pipelines is transitioning from a period of technological reserves to a period of clinical realization, with subsequent heavyweights entering the fast lane.